Literature DB >> 28830884

Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis.

Kensuke Oryoji1, Kenji Yoshida1, Yusuke Kashiwado2, Keiko Tanaka3,4, Shin-Ichi Mizuki1, Hiroshi Tsukamoto2, Kazuo Kamada1, Koichi Akashi2.   

Abstract

Entities:  

Keywords:  Ant-ccp; Dmards (biologic); Pharmacogenetics; Rheumatoid Arthritis

Mesh：

Substances：

Year:  2017        PMID： 28830884     DOI： 10.1136/annrheumdis-2017-211430

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  High serum IgA and activated Th17 and Treg predict the efficacy of abatacept in patients with early, seropositive rheumatoid arthritis.

Authors:  Jun Inamo; Yuko Kaneko; Jun Kikuchi; Tsutomu Takeuchi
Journal:  Clin Rheumatol       Date:  2021-03-11       Impact factor: 2.980

2.  A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity.

Authors:  Sang Hee Park; Xue Han; Francis Lobo; Sakina Nanji; Dipen Patel
Journal:  Clinicoecon Outcomes Res       Date:  2020-10-15

3.  The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity.

Authors:  Joe Zhuo; Qian Xia; Niyati Sharma; Sheng Gao; Sonie Lama; Jing Cui; Vivi Feathers; Nancy Shadick; Michael E Weinblatt
Journal:  Rheumatol Ther       Date:  2022-02-16

Review 4.  Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search.

Authors:  Nadia M T Roodenrijs; Paco M J Welsing; Joël van Roon; Jan L M Schoneveld; Marlies C van der Goes; György Nagy; Michael J Townsend; Jacob M van Laar
Journal:  Rheumatology (Oxford)       Date:  2022-08-30       Impact factor: 7.046

5.  Fusion proteins of biologic agents in the treatment of rheumatoid arthritis (RA): A network meta-analysis.

Authors:  Mingcai Wu; Mengjun Tao; Quanhai Wang; Xiaohua Lu; Hui Yuan
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

Review 6.  Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice.

Authors:  Tomasz Wysocki; Marzena Olesińska; Agnieszka Paradowska-Gorycka
Journal:  Cells       Date:  2020-05-02       Impact factor: 6.600

7.  Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.

Authors:  Leslie R Harrold; Joshua Bryson; Thomas Lehman; Joe Zhuo; Sheng Gao; Xue Han; Amy Schrader; Sabrina Rebello; Dimitrios A Pappas; Tanya Sommers; Joel M Kremer
Journal:  Rheumatol Ther       Date:  2021-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.